Non-alcoholic fatty liver disease (NAFLD) sits at the crossroads of obesity, insulin resistance and metabolic syndrome, yet no drug is approved specifically to reverse it. This article examines what the research literature actually reports about cagrilintide, a long-acting amylin analogue, and where its liver-relevant evidence is direct, indirect, or still confined to preclinical models.

The NAFLD research problem

NAFLD — increasingly reclassified in the recent literature as metabolic dysfunction-associated steatotic liver disease (MASLD) — describes fat accumulation in hepatocytes in the absence of significant alcohol intake. A meta-analytic assessment estimated global prevalence at roughly 25% of adults, with the highest burden reported in the Middle East and South America and the strongest comorbidity clustering around obesity, type 2 diabetes and dyslipidaemia.¹ A subset progresses from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and, in some cases, cirrhosis or hepatocellular carcinoma.

Where does the fat come from? Stable-isotope tracing in biopsy-confirmed NAFLD patients quantified the sources of stored hepatic triglyceride: about 59% derived from circulating non-esterified fatty acids, roughly 26% from hepatic de novo lipogenesis and around 15% from the diet.² That breakdown matters for any candidate compound, because it means two of the largest fat inflows — peripheral fatty-acid delivery and lipogenesis — are downstream of systemic energy balance and insulin signaling rather than the liver in isolation. Interventions that reduce adiposity and improve insulin sensitivity therefore have a plausible, if indirect, route to lowering liver fat.

The clinical stakes extend past the liver itself. A meta-analysis of 16 observational studies covering more than 34,000 adults found that NAFLD was associated with a higher risk of fatal and non-fatal cardiovascular events (odds ratio 1.64), with a stronger association in more severe disease — though the authors stressed that observational data cannot establish causation.³ This is why metabolic researchers frame fatty liver as a whole-body signal, and why weight-directed compounds are of interest as experimental tools.

What cagrilintide is

Cagrilintide is a long-acting synthetic analogue of amylin, a 37-amino-acid peptide co-secreted with insulin by pancreatic beta cells. Native amylin has a short circulating half-life that limits its research and therapeutic utility; cagrilintide was engineered for extended action, supporting once-weekly subcutaneous administration in trial settings.⁵ Mechanistically it acts as an agonist at amylin and related calcitonin-family receptors, which are concentrated in the hindbrain area postrema and hypothalamic circuits that govern satiety and gastric emptying.⁴

Its pharmacological logic differs from that of GLP-1 receptor agonists. Where GLP-1 analogues such as semaglutide act largely through incretin and gut–brain pathways, amylin analogues engage a parallel satiety system. That complementarity is the basis for co-administration research, in which cagrilintide and semaglutide are combined (the investigational fixed-dose combination is referred to in trials as CagriSema). Multi-target metabolic candidates such as retatrutide reflect the same broader research theme of layering appetite- and glucose-regulating mechanisms.

It is worth stating plainly: as of 2026, cagrilintide is an investigational compound. It has not received FDA approval as a standalone agent, and no regulator has cleared it for NAFLD, NASH or MASLD. Its appearance in the metabolic literature is a research story, not an approved-therapy story.

How amylin signaling could reach the liver

There is no evidence that cagrilintide clears liver fat by acting on hepatocytes in humans. The mechanistic hypothesis that connects it to NAFLD runs mostly through the brain and body composition, not directly through the liver.

Central appetite regulation

By agonising amylin receptors in the area postrema and hypothalamus, amylin analogues enhance satiety signaling and slow gastric emptying, which in experimental settings lowers caloric intake.⁴ Sustained reduction in energy intake is the proximate driver of the weight loss observed in cagrilintide trials.⁵

Indirect lipid effects

Because a majority of hepatic triglyceride originates from peripheral non-esterified fatty acids,² a reduction in adipose mass and an improvement in insulin sensitivity would be expected to lower the fatty-acid flux delivered to the liver. This is a plausible mechanistic chain, but in the case of cagrilintide it remains inferred from weight and metabolic parameters rather than measured directly in liver tissue.

A possible direct hepatic signal — preclinical only

A review of amylin and calcitonin pharmacology noted that, in rats, dual amylin and calcitonin receptor agonists produced body-weight loss, improved glucose tolerance and decreased fat deposition in liver tissue beyond what weight loss alone would predict — while explicitly cautioning that the translational relevance of these preclinical data remains unknown.⁴ In other words, a direct liver effect is biologically conceivable but currently rests on rodent data, not human confirmation.

Weight loss as the indirect lever on liver fat

Because cagrilintide's liver rationale runs through weight, the most relevant human data come from studies linking weight reduction to hepatic outcomes with other interventions. In a prospective lifestyle-modification cohort of patients with biopsy-proven NASH, the magnitude of weight loss tracked closely with histological improvement, and the effect was dose-dependent.¹⁰

These figures come from a lifestyle study, not from cagrilintide, and they describe correlation within a treated cohort rather than a guaranteed response. Their relevance here is conceptual: they establish why a compound that produces meaningful, sustained weight loss is of research interest for fatty-liver models. A related post-hoc analysis of the same population reported that histological improvement was independently associated with improved kidney function, underscoring how liver, metabolic and systemic endpoints move together.¹¹

The open question — unresolved for cagrilintide specifically — is whether pharmacologically induced weight loss yields the same histological benefit as lifestyle-induced weight loss, and whether any component of the effect is independent of weight.

What the clinical evidence actually shows

Cagrilintide's human trial record is real and substantial, but it is a weight-and-glucose record, not a liver record.

Cagrilintide monotherapy

In a multicentre, randomised, double-blind, placebo- and active-controlled dose-finding phase 2 trial in people with overweight or obesity without diabetes, once-weekly cagrilintide (0.3–4.5 mg) produced mean weight reductions of about 6.0% to 10.8% versus 3.0% with placebo over 26 weeks, and the 4.5 mg dose exceeded liraglutide 3.0 mg; the most common adverse events were gastrointestinal.⁵ No liver-imaging or histological endpoint was reported.

Cagrilintide plus semaglutide

A phase 1b trial co-administering ascending doses of cagrilintide with semaglutide 2.4 mg found the combination tolerable, with weight reductions in the mid-teens percentage range at higher cagrilintide doses and no adverse effect on semaglutide exposure.⁶ A subsequent 32-week phase 2 trial in type 2 diabetes reported that the combination lowered HbA1c by about 2.2 percentage points and reduced body weight by roughly 15.6%, greater than either component alone for weight.⁷ More recently, a phase 3a trial in an east-Asian population reported an estimated 18.4% weight reduction with cagrilintide–semaglutide versus 11.9% with semaglutide alone over 68 weeks.⁸ These are weight-management and glycaemic outcomes; none measured hepatic steatosis directly.

The GLP-1 proxy for liver endpoints

The closest histological read-through comes from the GLP-1 side of the combination. In a 72-week phase 2 trial in biopsy-confirmed NASH, subcutaneous semaglutide achieved NASH resolution without worsening of fibrosis in 59% of patients at the 0.4 mg dose versus 17% with placebo — but the trial did not show a statistically significant difference in fibrosis-stage improvement.⁹ This demonstrates that a weight-active metabolic peptide can move liver histology, while also illustrating how partial and endpoint-specific such effects can be. It is a proxy, not evidence for cagrilintide itself.

Beyond liver fat: the metabolic context

NAFLD rarely travels alone, so researchers examine cagrilintide against the wider metabolic cluster.

Cardiometabolic parameters

Given the documented association between NAFLD and cardiovascular events,³ the weight and glycaemic changes reported in cagrilintide combination trials⁷ are of interest as potential upstream modifiers of cardiometabolic risk factors. Whether they translate into hard cardiovascular outcomes is a separate, longer question not answered by the existing phase 2 data.

Insulin sensitivity and glucose control

Improved glycaemic parameters observed across cagrilintide combination cohorts⁶⁷ are mechanistically relevant to NAFLD, because insulin resistance drives both peripheral fatty-acid release and hepatic de novo lipogenesis.² Again, this is a coherent mechanistic narrative rather than a demonstrated liver outcome.

Fibrosis

Fibrosis stage is the histological feature most tightly linked to long-term liver outcomes, and it is precisely where evidence is thinnest. The semaglutide NASH trial failed to show a significant fibrosis benefit despite strong resolution rates,⁹ a reminder that steatosis reduction and fibrosis regression are not the same target and should not be conflated when reasoning about cagrilintide.

Limitations and open questions

Several caveats define the current state of this research area. First, there is a direct-evidence gap: no published cagrilintide trial has used liver fat or histology as an endpoint, so every liver claim is inferential. Second, the direct-hepatic-effect hypothesis is preclinical and rodent-based.⁴ Third, tolerability is dominated by gastrointestinal adverse events across trials,⁵⁶ which shapes dose-finding in experimental protocols. Fourth, response is heterogeneous, and the durability of any metabolic benefit beyond the trial windows studied so far remains uncharacterised.

For laboratories designing mechanistic work, these gaps are also the opportunities: distinguishing weight-dependent from weight-independent hepatic effects, comparing amylin-analogue and GLP-1 pathways head to head on liver-fat readouts, and modelling fibrosis rather than steatosis. High-purity, well-characterised research material is a prerequisite for any of it.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.